849475-89-4

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydroxy-2-pyridin-2-yl-pyrimidine-4-carboxylic acid methyl ester is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows for the development of bioactive compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5,6-Dihydroxy-2-pyridin-2-yl-pyrimidine-4-carboxylic acid methyl ester serves as a building block in the production of agrochemical compounds. Its versatile chemical properties enable the creation of effective compounds for agricultural and pest control purposes.
As a Research Compound:
5,6-Dihydroxy-2-pyridin-2-yl-pyrimidine-4-carboxylic acid methyl ester is also used as a research compound for studying its potential biological activities and exploring its applications in various fields. Its unique structure provides opportunities for further investigation and development of new compounds with specific properties and functions.

Upstream product

• 762-42-5 dimethyl acetylenedicarboxylate 
• 1772-01-6 N'-hydroxypyridine-2-carboximidamide 
• 1772-01-6 2-pyridylamidoxime 
• 100-70-9 2-Cyanopyridine 
• 1772-01-6 (Z)-N'-hydroxy-pyridine-2-carboxamidine 

Downstream Products

• 786638-23-1 N-benzyl-5,6-dihydroxy-2-(pyridin-2-yl)pyrimidine-4-carboxamide 
• 1407169-99-6 N-cyclohexyl-5,6-dihydroxy-2-(pyridin-2-yl)pyrimidine-4-carboxamide 

Relevant academic research and scientific papers

5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein

The HIV-1 nucleocapsid (NC) protein is a small basic DNA and RNA binding protein that is absolutely necessary for viral replication and thus represents a target of great interest to develop new anti-HIV agents. Moreover, the highly conserved sequence offers the opportunity to escape the drug resistance (DR) that emerged following the highly active antiretroviral therapy (HAART) treatment. On the basis of our previous research, nordihydroguaiaretic acid 1 acts as a NC inhibitor showing moderate antiviral activity and suboptimal drug-like properties due to the presence of the catechol moieties. A bioisosteric catechol replacement approach led us to identify the 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new class of HIV-1 NC inhibitors. Hit validation efforts led to the identification of optimized analogs, as represented by compound 28, showing improved NC inhibition and antiviral activity as well as good ADME and PK properties.

COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND F1BROTIC DISEASE

Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a method for assaying such compositions.

HIV-1 NUCLEOCAPSID INHIBITORS

The present invention discloses novel anti-HIV agents targeting the HIV Nucleocapsid protein (NC), which is one of the most conserved sequences within HIV strains and is highly required for HIV replication. The compounds of the invention are particularly useful to overcome antiretroviral drug-resistance in HIV-1 infected individuals.

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.